EN DE
STOCK COMPARISON

Medpace Holdings vs Thermo Fisher Scientific: Fair Value & Quality

Both stocks run through our valuation models. Here is how Medpace Holdings (MEDP) and Thermo Fisher Scientific (TMO) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: Medpace Holdings trades at $585 versus a fair value of $287 (-51%), while Thermo Fisher Scientific trades at $580 versus $308 (-47%).
Medpace Holdings
MEDP · USD · Health Care
-51%
upside to fair value
overvalued
Price$585
Fair Value$287
Quality80/100
Thermo Fisher Scientific
TMO · USD · Health Care
-47%
upside to fair value
overvalued
Price$580
Fair Value$308
Quality64/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Medpace HoldingsThermo Fisher Scientific
Valuation
33.8×P/E (TTM)29.5×
5.72×P/S (TTM)4.41×
33.35×P/B3.74×
25.2×EV/EBITDA20.0×
3.30×PEG1.74×
Dividend yield0.3%
Dividend per share$1.76
Profitability
17%Net margin15%
20%Operating margin18%
77%Return on equity14%
17%Return on assets5%
Growth
27%Revenue growth (YoY)6%
20.1%Avg. growth/yr (3Y)-0.3%
22.3%Avg. growth/yr (5Y)6.7%
Balance & size
0.17×Debt / equity0.67×
$15BMarket cap$199B
healthyGrowth qualityhealthy

Medpace Holdings leads: 8 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Medpace Holdingsof which business quality 84 · market factors 64 Thermo Fisher Scientificof which business quality 60 · market factors 63
ProfitabilityMargins and returns on capital today
89
43
Quality GrowthAre margins and returns improving?
72
31
CashflowEarnings quality: real cash, not paper profit
92
62
Fin. StrengthBalance sheet, leverage, solvency risk
79
60
InvestmentDisciplined investing over empire-building
68
79
Low VolatilityCalm price path (market factor)
40
68
MomentumPrice trend over the last 3–12 months (market factor)
70
56
52W MomentumDistance to the 52-week high (market factor)
81
68
Net IssuanceBuybacks instead of dilution
100
97

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Medpace Holdings

DCF Models$565
Earnings-Based$345
Dividend Discount$7.01
Multiples$253
Asset-Based$10.77
Growth DCF$579
Economic Profit$246
Growth Earnings$451

22 of 26 models see the stock below the current price.

Thermo Fisher Scientific

DCF Models$331
Earnings-Based$203
Multiples$310
Asset-Based$96.29
Growth DCF$288
Economic Profit$159
Growth Earnings$324

24 of 24 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Medpace Holdings
Bear $215Fair Value $287Bull $609
$585 = current price (white tick)
Thermo Fisher Scientific
Bear $175Fair Value $308Bull $385
$580 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Medpace Holdings · Health Care

Quality score80 · Top 25%
Fair value upside-51% · below median

Thermo Fisher Scientific · Health Care

Quality score64 · Top 25%
Fair value upside-47% · below median

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees Thermo Fisher Scientific as the less overvalued of the two: Medpace Holdings trades at $585 versus a fair value of $287 (-51%), while Thermo Fisher Scientific trades at $580 versus $308 (-47%).

Medpace Holdings has the higher quality score (80/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.